
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Holdings Inc. has demonstrated a notable increase in Research and Development (R&D) expenses, reflecting a commitment to advancing its product candidates, with expenses rising by 21% year-over-year to $14.0 million and projected to reach $58.2 million in 2025, a 36% increase from the prior year. Furthermore, the company's Selling, General & Administrative (SG&A) expenses also experienced growth, increasing by 12% to $26.9 million, indicative of an investment in operational capabilities that support its strategic goals. The reliance on commercial partners to penetrate target markets and increase sales of its innovative medical technologies positions the company for potential revenue growth as these partnerships evolve.
Bears say
Orchestra BioMed Holdings Inc. has faced ongoing operating losses since its inception, reflecting its status as a development-stage company. The persistent history of losses raises concerns about the company's ability to achieve and maintain profitability in the future. Additionally, these financial challenges could hinder the company's long-term growth prospects and investor confidence in its product candidates.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares